Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Lung and Upper Aerodigestive Cancer
Sponsor
National Cancer Institute (NCI)
Status
Active, not recruiting
NCT ID
NCT02581137
This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off and can be associated with a higher risk of cancer. Metformin hydrochloride may help prevent oral cancer from forming in patients with an oral premalignant lesion.
Intervention
Laboratory Biomarker Analysis, Metformin Hydrochloride
Condition
Erythroplakia, Hyperplasia, Oral Cavity Carcinoma, Oral Leukoplakia
Investigators
Scott M Lippman